MedTrace Logo

Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

NCT04561466 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-09-22

No results posted yet for this study

Summary

Study of the efficiency of Béfizal® 200 mg in 14 adult patients with a LHON that occurred for less than 5 years. Patient must have certain specific mutations

Conditions

  • Safety Issues
  • Efficacy, Self

Interventions

DRUG

Béfizal

600 mf befizal a day for one year

Sponsors & Collaborators

  • European Georges Pompidou Hospital

    collaborator OTHER

  • CLAIROP

    collaborator UNKNOWN

  • Hôpital Necker-Enfants Malades

    lead OTHER

Principal Investigators

  • Dominique Bremond Gignac, MD PhD · Necker Hopsital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2022-12-09
Completion
2023-03-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04561466 on ClinicalTrials.gov